Lonafarnib

TargetMol
Product Code: TAR-T6302
Supplier: TargetMol
CodeSizePrice
TAR-T6302-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6302-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6302-10mg10mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6302-1mL1 mL * 10 mM (in DMSO)£205.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6302-25mg25mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6302-50mg50mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6302-100mg100mg£627.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9/5.2/2.8 nM).
CAS:
193275-84-2
Formula:
C27H31Br2ClN4O2
Molecular Weight:
638.83
Pathway:
GPCR/G Protein; MAPK; Metabolism; Autophagy
Purity:
0.98
SMILES:
NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1
Target:
Raf; Transferase; Autophagy; Ras

References

Tangliang Zhao1*, Yi Bao1*,Xinxin Gan1, et al. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma. Theranostics. 2019, Vol. 9, Issue 21 Chun KH, et al. Cancer Res, 2003, 63(16), 4796-4800. Sun SY, et al. J Biol Chem, 2007, 282(26), 18800-18809. Liu M, et al. Cancer Res, 1998, 58(21), 4947-4956. Tangliang Zhao1*, Yi Bao1*,Xinxin Gan1*, Jie Wang1*, Qiong Chen1*, Zhihui Dai2*, Bing Liu 1, Anbang Wang1, Shuhan Sun2, Fu Yang2,3?, Linhui Wang1 DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma. Theranostics. 2019, Vol. 9, Issue 21 Feldkamp MM, et al. Cancer Res, 2001, 61(11), 4425-4431.